Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $51,691.04 in Stock

Key Points

• Nurix Therapeutics CFO Houte Hans Van sold 4,304 shares for a total of $51,691.04, reducing his ownership by 9.52% to approximately 40,914 shares valued at $491,377.14.
• Nurix reported earnings of ($0.52) per share, exceeding estimates, and generated revenues of $44.06 million, significantly higher than the consensus estimate of $16.26 million.
• Analysts maintain a consensus rating of "Moderate Buy" for Nurix, with an average price target of $29.31, despite some recent adjustments from various research firms.

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 4,304 shares of the business's stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total transaction of $51,691.04. Following the sale, the chief financial officer owned 40,914 shares of the company's stock, valued at $491,377.14. This trade represents a 9.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Houte Hans Van also recently made the following trade(s):

• On Friday, May 2nd, Houte Hans Van sold 6,198 shares of Nurix Therapeutics stock. The stock was sold at an average price of $11.33, for a total transaction of $70,223.34.

Nurix Therapeutics Trading Down 2.0%

NRIX traded down $0.22 during trading on Friday, hitting $11.04. 533,693 shares of the company traded hands, compared to its average volume of 888,161. The company has a market cap of $844.00 million, a PE ratio of -4.23 and a beta of 2.15. The stock's 50-day simple moving average is $11.79 and its two-hundred day simple moving average is $13.13. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.27. The company had revenue of $44,056 billion for the quarter, compared to the consensus estimate of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. Equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st. Oppenheimer reiterated an "outperform" rating and issued a $30.00 price target (down from $32.00) on shares of Nurix Therapeutics in a research report on Thursday. UBS Group dropped their price target on shares of Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating for the company in a research report on Thursday, July 10th. Needham & Company LLC reiterated a "buy" rating and issued a $27.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Finally, HC Wainwright dropped their target price on shares of Nurix Therapeutics from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Monday, July 14th. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $28.87.

Institutional Investors Weigh In On Nurix Therapeutics

Hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new stake in Nurix Therapeutics during the fourth quarter valued at $28,000. Aquatic Capital Management LLC purchased a new stake in Nurix Therapeutics during the fourth quarter valued at $87,000. Exchange Traded Concepts LLC raised its stake in Nurix Therapeutics by 38.9% during the first quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company's stock valued at $109,000 after purchasing an additional 2,562 shares in the last quarter. E Fund Management Co. Ltd. purchased a new stake in Nurix Therapeutics during the first quarter valued at $122,000. Finally, Summit Investment Advisors Inc. raised its stake in Nurix Therapeutics by 13.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock valued at $138,000 after purchasing an additional 877 shares in the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.